China Medical Technologies
China Medical Technologies was a China-based medical-diagnostics and therapeutic-technology company that entered liquidation after alleged large-scale securities fraud and insolvency.
Last updated November 4, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
China Medical Technologies, Inc. (CMED) was a Cayman Islands-incorporated company operating from China and presenting itself as a developer, manufacturer, and marketer of medical technologies. Its stated business combined high-intensity focused ultrasound therapy with several advanced in-vitro and molecular diagnostic platforms. The company promoted a focused-ultrasound system identified as model FEP-BY02 and diagnostic offerings based on enhanced chemiluminescence immunoassay (ECLIA), fluorescent in-situ hybridization (FISH), and surface plasmon resonance (SPR). The intended applications included the detection and monitoring of endocrine disorders, diabetes, hepatitis, liver fibrosis, reproductive and growth conditions, genetic diseases, human papillomavirus infection, and cancers. CMED was incorporated in 2004 and accessed U.S. capital markets through an initial public offering of American depositary shares in 2005. Its ADSs were quoted on the NASDAQ National Market and later listed on the Nasdaq Global Select Market. The company also raised substantial debt through note offerings. According to the cited account, CMED raised approximately $677 million through stock and bond transactions between its 2005 IPO and December 2010. Its financing story was therefore central to its identity: although it described itself as a specialized Chinese medical-technology enterprise, it was also a highly leveraged, publicly traded issuer dependent on continued investor confidence and access to capital. The company’s commercial portfolio was organized around diagnostic instruments and consumables. Its ECLIA business was described as an integrated analyzer-and-reagent-kit system. Its FISH business consisted of imaging analyzers and molecular probes intended for prenatal and postnatal genetic diagnosis and cancer assessment. Its SPR business included an SPR system and HPV-DNA chips designed for label-free HPV detection and genotyping. The company also claimed a therapeutic role through its high-intensity focused ultrasound equipment. Available source material describes these activities as purported businesses; the later insolvency proceedings and criminal allegations substantially undermined the credibility of CMED’s public disclosures and business representations. Warning signs emerged before the company ceased operating. In 2009, an anonymous letter sent to KPMG Hong Kong alleged possible illegal and fraudulent conduct by management dating from 2007. CMED’s audit committee retained Paul Weiss Rifkind Wharton & Garrison to investigate. The company announced substantial completion of that internal investigation in July 2009, but disputes over the investigation’s records continued after CMED became insolvent. CMED stopped operating in early 2012 and failed to pay interest on approximately $426 million of bond debt. Its securities were progressively removed from U.S. public markets: the ADSs moved from NASDAQ to the pink sheets in February 2012, were delisted from NASDAQ in March, and the company’s ordinary shares were deregistered in June. In July 2012, joint official liquidators appointed under an order of the Grand Court of the Cayman Islands took control. CMED filed for Chapter 15 bankruptcy protection in the United States in August 2012, reporting roughly $500 million in assets and liabilities, while winding-up proceedings also took place in Hong Kong. The liquidation became an international fraud investigation. Liquidators alleged that creditors and equity holders might have been victims of a multiyear insider-fraud scheme and investigated missing proceeds from stock and bond offerings. In 2012, they referred allegations to Hong Kong police and the FBI. Civil litigation was filed by investors and bond purchasers, and later court proceedings addressed access to materials from the earlier Paul Weiss investigation. In March 2017, U.S. prosecutors indicted founder and former chief executive Xiaodong Wu and former chief financial officer Tak Yung Samson Tsang, alleging securities fraud and wire-fraud conspiracy involving more than $400 million. The allegations included misleading investors about the use of note proceeds, diverting funds to controlled entities, suppressing material disclosures, and ceasing interest payments. These were criminal allegations, not a finding stated here as a final adjudication. By the late 2010s, CMED was no longer an operating medical-technology brand. Its corporate legacy was dominated by liquidation, unpaid creditors, delisting, regulatory action, litigation, and investigations concerning the reliability of its financial and technological claims.
History
China Medical Technologies was incorporated in the Cayman Islands in 2004 and operated from China. It presented itself as a medical-technology enterprise focused on diagnostic systems, molecular testing, and high-intensity focused ultrasound. The business described an FEP-BY02 ultrasound system alongside ECLIA, FISH, and SPR platforms. ECLIA analyzers and reagent kits were associated with testing areas such as thyroid disease, diabetes, hepatitis, liver fibrosis, reproductive and growth disorders, Down syndrome, and tumors. FISH analyzers and probes were intended for genetic and oncology applications, while SPR equipment and HPV-DNA chips were described as tools for HPV detection and genotyping. The company entered U.S. public markets in 2005 through an offering of ADSs. Its securities were later listed on the Nasdaq Global Select Market. CMED also used bond and note offerings to raise capital, reportedly collecting about $677 million from stock and bond sales between August 2005 and December 2010. Credit Suisse and Morgan Stanley participated in a 2008 share offering, and Credit Suisse handled a $150 million debt offering. Concerns about management conduct surfaced publicly in 2009, when an anonymous letter sent to the company’s auditor alleged illegal and fraudulent activity dating from 2007. The audit committee commissioned Paul Weiss to investigate, and CMED announced substantial completion of that review in July 2009. The investigation later became part of liquidation-related discovery disputes. CMED ceased operating in early 2012 and defaulted on interest obligations tied to approximately $426 million of bonds. Its ADSs shifted from NASDAQ to the pink sheets in February, were delisted in March, and its ordinary shares were deregistered in June. From July 2012, joint official liquidators appointed by the Grand Court of the Cayman Islands controlled the company. CMED filed for Chapter 15 protection in August, while related winding-up proceedings were pursued in Hong Kong. The U.S. Securities and Exchange Commission revoked the registration of its securities in November. The liquidators investigated alleged insider fraud and suspected diversion of capital raised from investors. Investor class actions and bondholder litigation were filed in the United States. In 2015, a federal judge ruled that Paul Weiss had to provide the liquidator with materials from its earlier internal investigation, rejecting the firm’s attempt to withhold the information under privilege in the bankruptcy context. In 2017, U.S. prosecutors indicted founder and former CEO Xiaodong Wu and former CFO Tak Yung Samson Tsang. The indictment alleged that the executives misrepresented the uses of note proceeds, diverted more than $400 million to entities they controlled, withheld material information, and stopped paying interest. Separately, liquidators pursued Hong Kong proceedings concerning KPMG audit records. CMED’s operating business did not recover, and the company’s enduring status became that of a defunct issuer under liquidation rather than an active medical brand.
- 2017
Former executives indicted
[1]U.S. prosecutors indicted Xiaodong Wu and Tak Yung Samson Tsang over alleged securities and wire-fraud conspiracy.
- 2015
Court orders production of internal-investigation materials
[1]A U.S. federal court ordered Paul Weiss to provide the liquidator with materials from its earlier CMED investigation.
- 2012
Operations cease and securities leave NASDAQ
[1]CMED stopped operating, defaulted on bond interest, moved to the pink sheets, and was delisted and deregistered in stages.
- 2012
Liquidation and Chapter 15 filing
[1]Joint official liquidators took control under Cayman Islands court authority, and CMED sought Chapter 15 bankruptcy protection in the United States.
- 2009
Internal investigation commissioned
[1]After an anonymous letter raised allegations about management, the audit committee retained Paul Weiss to conduct an investigation.
- 2008
Further equity and debt financing
CMED completed additional public-market financing, including a share offering and a $150 million debt offering described in the source material.
- 2006
ADSs move to Nasdaq Global Select Market
[1]Following changes in NASDAQ’s regulatory status, CMED’s ADSs became listed on the Nasdaq Global Select Market.
- 2005
U.S. ADS offering
[1]CMED registered its ordinary shares and completed an initial offering of American depositary shares quoted on NASDAQ.
- 2004
Company incorporated
[1]China Medical Technologies was incorporated in the Cayman Islands and operated as a China-based medical-technology company.
Products and positioning
A China-based specialist medical-technology company positioned around diagnostic platforms, molecular testing, and focused-ultrasound therapy; its public-market identity later became inseparable from insolvency and alleged securities fraud.
High-intensity focused ultrasound therapy system
FEP-BY02
A focused-ultrasound therapy system that CMED identified as part of its therapeutic-technology portfolio. The available reference describes the system by model number but does not establish its current commercial availability, regulatory footprint, or clinical adoption.
In-vitro diagnostics
ECLIA analyzer and reagent kits
An enhanced chemiluminescence immunoassay platform combining analyzers with reagent kits. CMED associated the system with testing for thyroid disorders, diabetes, hepatitis, Down syndrome, liver fibrosis, reproductive and growth conditions, and various tumors.
Molecular diagnostics
FISH imaging analyzer and probes
A fluorescent in-situ hybridization diagnostic system consisting of an imaging analyzer and molecular probes. The stated uses included prenatal and postnatal diagnosis of genetic diseases and early detection or prognosis of cancers.
Molecular diagnostics
SPR system and HPV-DNA chips
A surface-plasmon-resonance platform paired with label-free HPV-DNA chips. The chips were described as tools for detecting HPV infection and determining HPV genotypes.
Controversies
2017
Former executives indicted over alleged investor fraud
The U.S. Department of Justice alleged that former CMED executives diverted more than $400 million from investors through securities-fraud and wire-fraud conspiracies. The charges are reported as allegations rather than a final conviction.
2017
KPMG audit-records contempt proceedings
CMED liquidators pursued Hong Kong contempt proceedings against KPMG partners over the alleged failure to provide Chinese working papers and related records required by a court order.
2012
Liquidators investigate alleged insider fraud
After CMED’s collapse, liquidators alleged that creditors and equity holders may have been harmed by a multiyear fraud involving missing or fraudulently transferred assets and referred allegations to law-enforcement bodies.
2009
Management-misconduct allegations and internal investigation
An anonymous letter alleged illegal and fraudulent activity by management since 2007. CMED’s audit committee retained Paul Weiss to investigate, and the resulting records later became the subject of court-ordered discovery.
Brand decisions
2012
Enter formal insolvency and liquidationOtherBackground
CMED ceased operations, defaulted on bond interest, and faced creditor claims and allegations of missing assets.
Action taken
Cayman Islands court-appointed liquidators took control, followed by a Chapter 15 bankruptcy filing in the United States.
Aftermath
The company’s securities were delisted or deregistered, and the operating brand became defunct while investigations and litigation continued.
Unpaid bond debt. Approximately $426 million (Early 2012)
2009
Commission an independent internal investigationOtherBackground
An anonymous complaint sent to CMED’s auditor alleged possible illegal and fraudulent management activity.
Action taken
The audit committee retained Paul Weiss Rifkind Wharton & Garrison to investigate the allegations and advise on next steps.
Aftermath
CMED announced substantial completion of the investigation, but the firm’s records were later sought by the liquidator and ordered produced by a U.S. court.
2005
Access U.S. public capital marketsStrategyBackground
CMED sought financing and visibility through a U.S. offering of American depositary shares.
Action taken
The company registered its securities and completed an ADS offering quoted on NASDAQ.
Aftermath
The offering became part of the company’s broader stock-and-bond fundraising program, later scrutinized in insolvency and fraud proceedings.
Reported stock and bond proceeds. Approximately $677 million (August 2005 through December 2010)
Recent events
- 2012
CMED moves from NASDAQ quotation to the pink sheets[1]
Regulation · Other
The company’s U.S. securities moved away from NASDAQ trading amid operational and financial distress.
- 2012
CMED ADSs delisted and ordinary shares deregistered[1]
Regulation
NASDAQ delisted the ADSs, and CMED’s ordinary shares were subsequently deregistered under U.S. securities law.
- 2012
CMED enters Chapter 15 bankruptcy protection[1]
Bankruptcy
The company sought U.S. recognition of its foreign insolvency proceedings after ceasing operations and defaulting on bond interest.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/china-medical-technologies · Editorial policy · How profiles are compiled